Mold-Help.org - The world's largest TOXIC MOLD website
  • Mold Basics
    • Mold Overview
    • Mold Symptoms
    • Mold Types & Images
    • Fungal Infections
  • Resources and Tools
    • Home Care
    • Health & Diet
    • Tips for Parents
    • Coping with Loss
    • Private Research
    • Legal Suggestions
    • Mold in the Bible
  • Mold News
    • Current Headlines
    • “Sick Buildings”
    • The Environment
    • Construction Industry
    • Govt. & Politics
    • The Workplace
    • Landlords & Tenants
    • Insurance Companies
    • Schools & Institutions
    • Strange Fungal Tales
    • Personal Mold Stories
    • Additional Articles
  • Agencies & Experts
  • About Mold-Help
    • Mold-Help News
  • Search
  • Menu Menu
  • Twitter
  • Facebook

Anti-Fungal Drug

October 3, 2004/in Additional Articles /by Carolyn Willbanks

Indevus Initiates Phase I Clinical Trial of Aminocandin for Systemic Fungal Infections

LEXINGTON, Mass. – Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced the initiation of a Phase I clinical trial with Zminocandin, a member of a new class of anti-fungal compounds under development for the treatment of a broad spectrum of systemic, invasive infections. This trial will test the safety and tolerability of escalating single doses of aminocandin administered intravenously in healthy volunteers. Results of the trial are expected in the second half of 2004.

“This trial will build upon an extensive pre-clinical dossier on aminocandin compiled by Aventis SA, from whom Indevus licensed exclusive worldwide rights to this compound in 2003,” said Glenn L. Cooper, M.D., chairman, president and chief executive officer of Indevus. “Findings will determine the safety of intravenously administered aminocandin in humans. In vitro and animal studies with aminocandin have demonstrated activity against a broad range of fungi and the ability to protect against systemic fungal infections in an immune-compromised host. We also believe aminocandin has the potential to be administered orally, and we have initiated feasibility studies related to the development of an oral formulation.”

Echinocandins are the first new class of anti-fungal agents to be developed and introduced in more than 40 years. They are designed to  be fungicidal, that is, to destroy fungi, rather than simply to inhibit their growth, and to have broad-spectrum activity against the
fungi that cause serious systemic infections.

According to reports from Datamonitor, Inc., an industry market research firm, the worldwide market for anti-fungal agents is currently valued in excess of $4 billion, of which approximately $2.5 billion relates to systemic, invasive fungal infections, and is
projected to grow to $6.5 billion by 2008, of which approximately one-half is predicted to represent systemic infections.

Indevus Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of a diversified portfolio of  pharmaceutical product candidates, including multiple compounds in development: trospium for overactive bladder, pagoclone for panic and generalized anxiety disorders, citicoline for ischemic stroke, IP 751 for pain and inflammatory disorders, PRO 2000 for the prevention of  infection by HIV and other sexually transmitted pathogens and aminocandin for systemic fungal infections.

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve  risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially from those anticipated  by the forward-looking statements. These risks and uncertainties are set forth in the Company’s filings under the Securities Act of 1933  and the Securities Exchange Act of 1934 under “Risk Factors” and elsewhere, and include, but are not limited to: dependence on the  success of trospium; the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly trospium; risks associated with contractual agreements; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners, including for the commercialization of trospium and for the development of pagoclone; failure to acquire and develop additional product candidates; history of operating losses  and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation;  limited patent and proprietary rights; dependence on market exclusivity; valuation of our Common Stock; risks related to  repayment of debts; risks related to increased leverage; and other risks.

Carolyn Willbanks
Author: Carolyn Willbanks

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Reddit
  • Share by Mail
https://www.mold-help.org/wp-content/uploads/2019/03/moldhelp-654x300.png 0 0 Carolyn Willbanks https://www.mold-help.org/wp-content/uploads/2019/03/moldhelp-654x300.png Carolyn Willbanks2004-10-03 21:02:302018-09-07 18:48:51Anti-Fungal Drug

Mold News

  • Current Headlines
  • "Sick Buildings"
  • The Environment
  • Construction Industry
  • Govt. & Politics
  • The Workplace
  • Landlords & Tenants
  • Insurance Companies
  • Schools & Institutions
  • Personal Mold Stories
  • Strange Fungal Tales
  • Additional Articles

Latest Posts

  • Michigan Family Finds Toxic Mold Inside Home
  • California Winter Storms: Water Damage and Mold Exposure Concerns in California
  • Office and Commercial Buildings at Risk for Mold after COVID-19 Closings
  • COVID-19 Symptoms May Include Loss of Taste and Smell
  • New Mold Detox Information on the Horizon
  • COVID-19 Courses of Action
  • Stachybotrys
  • Simple and Easy Ways to Prevent the Coronavirus
  • Your Air Conditioning Unit Helps Eliminate Mold
  • Construction Workers Are Learning to Control Dust and Debris

Search Our Site:

Need Help with Mold?

Are you being affected by mold or other mycotoxins in your environment? Our team and community has over 15 years experience and can provide guidance. You can reach us by submitting your contact or through our Facebook page.

Have a Story to Share?

We're looking for stories and input to expand our database and to add to the personal experiences we've received from the thousands of victims over the last 15. If mold has impacted your life, please take the time to share your story. Your information is confidential and will only be shared with your permission.

Seeking Mold Experts

Are you an expert in the treatment of mold-affected health illnesses, or a provider of services to victims of mycotoxin exposure? Submit your information for listing consideration in our Agencies & Experts resource database.

Additional Resources

  • Contact Us
  • Sitemap
  • Glossary of Terms
  • Survivor Resources
  • General Inquiries
  • Legal Disclaimer

© Copyright - Mold-Help Organization
  • Twitter
  • Facebook
  • Mold Basics
  • Resources and Tools
  • Agencies & Experts
  • Mold News
  • About Mold-Help
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only